Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PolyPid Ltd.
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
The latest drug development news and highlights from our US FDA Performance Tracker.
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific